Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study.
Session Meet the Trialist IV: ODYSSEY COMBO II - ODYSSEY FH I and FH II - ODYSSEY LONG TERM
Speaker Christopher Paul Cannon
Event : ESC Congress 2014
- Topic : preventive cardiology
- Sub-topic : Risk Factors and Prevention
- Session type : Meet the Trialists